Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy
about
Treatment for lupus nephritisLong-term data on tacrolimus treatment in lupus nephritis.The pathology of T cells in systemic lupus erythematosusCurrent status of lupus nephritis.Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study.Recent clinical trials in lupus nephritis.Cyclophosphamide and lupus nephritis: when, how, for how long?Systemic lupus erythematosus: review of synthetic drugs.Renal involvement in autoimmune connective tissue diseases.ESRD from lupus nephritis in the United States, 1995-2010An approach to validating criteria for proteinuric flare in systemic lupus erythematosus glomerulonephritis.Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis.The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease.The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.Understanding lupus nephritis: diagnosis, management, and treatment options.A Meta-Analysis on Prehypertension and Chronic Kidney Disease.Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients.American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisJoint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.Lupus nephritis in children - 10 years' experience.Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment.TAC-TIC use of tacrolimus-based regimens in lupus nephritis.Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions.Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians.Recent advances in the treatment of lupus nephritis.Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus.NFAT gene family in inflammation and cancer.Overview of lupus nephritis management guidelines and perspective from Asia.Top 10 developments in lupus nephritis.Overview of lupus nephritis management guidelines and perspective from Asia.Treatment of severe lupus nephritis: the new horizon.Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study.Reviewing the recommendations for lupus in children.Lupus nephritis management guidelines compared.Risk factors for renal disease in systemic lupus erythematosus and their clinical implications.IgG4-related disease and the kidney.Pharmacokinetic modeling of therapies for systemic lupus erythematosus.Lupus nephritis: an update.
P2860
Q24202572-C67E589D-F0F7-466F-895A-6DCA09D9CEA5Q30835209-01B94BC4-7339-4AA9-B026-96E75619BE33Q33598213-546DD4D8-CD84-4DB6-B94B-CFECE5B951BCQ33882751-3630BFEE-0DD5-4FB3-BCED-71E14459A3B3Q33885872-0DFC7DED-4CC8-4F0C-BA71-8F7DD98B5EBBQ33924437-329B16D4-FEC2-4FE5-9DBE-2B0694F8DE66Q34095231-D3B231D4-B581-400B-9CAE-58CF88992823Q34498515-5738DB45-12AE-447A-92A0-FBFD023B74B3Q34654954-2FD76045-7430-404A-9FDC-78531CDDA822Q35051164-9EEA2AB6-E85F-4258-B486-829741E30244Q35053510-A4474E81-D7BE-4D5D-A328-D0C32E4475DFQ35187502-3A04AF07-A3B9-41D6-8CF5-375BEAC06731Q35574235-506564FD-C527-45F3-95E5-DE3A61C9AAC4Q35897121-DFB516B7-8F50-4EAC-B720-DDE2AC4F564FQ36008840-BA0F4AEC-7D02-4EC4-BB6D-1217537710CFQ36036055-19BECE13-0A42-4498-83B0-9E470F859878Q36084894-1B7410ED-827A-405F-B15F-F80343B6C3CDQ36221407-D7055475-62C9-4D89-9BF0-8F0A6DB1D9F5Q36302245-CED8DCB1-0BB1-4C87-A45B-1C1868F6AED4Q37399315-95C1153C-EC85-425B-B1CA-70A5330A9242Q37403811-CA882D9B-0609-48E6-A708-3D937A81205CQ37587317-7EB56D9C-1614-4972-BE2A-3B7747EF3856Q37671987-C5CF197E-C35A-4D20-A2E7-A438515D9BCAQ37678723-AE984785-997A-4B66-B613-2958B3BEB586Q37857737-28554C47-7EDB-4FBA-962B-AD5C21A5E15CQ37953243-FA2C4C48-4630-4A69-9EC5-20832E9F78E3Q37954539-B97D1B10-5FB4-43D7-86B0-1CB3F4AECBECQ37960525-41E758CA-B1D3-47ED-91EB-F6FEA511B720Q38040813-F71958B8-410B-480F-8463-9F4B17DA7D5AQ38123242-8872FA92-B829-4844-869E-42FC0D540CDFQ38124761-0C229E43-FCC0-4761-B088-38AB663F6802Q38175076-B7B85B68-7809-4480-9238-A98DE7374FC2Q38271125-6429F834-CFF5-4F39-B6A2-178AA292C4F4Q38372154-69F096BA-9DAD-4B51-A98C-FAA40D8CED81Q38374309-8F09883E-A9B9-4EFA-B8E4-7C4786A44211Q38446941-CA0F343C-A2BE-4FA1-AD31-E81281879084Q38479339-ADC9CF92-0AC4-4C66-97A9-75EE19DBAE86Q38540095-526EC54A-943D-452F-9F3D-82FFA48016D7Q38542910-66AC237E-8800-4C8F-9D9A-C4296FDCD79BQ38608138-D351A4B1-62F0-481E-A74D-29B083A4A356
P2860
Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Randomized, controlled trial o ...... n lupus membranous nephropathy
@en
Randomized, controlled trial o ...... lupus membranous nephropathy.
@nl
type
label
Randomized, controlled trial o ...... n lupus membranous nephropathy
@en
Randomized, controlled trial o ...... lupus membranous nephropathy.
@nl
prefLabel
Randomized, controlled trial o ...... n lupus membranous nephropathy
@en
Randomized, controlled trial o ...... lupus membranous nephropathy.
@nl
P2093
P2860
P356
P1476
Randomized, controlled trial o ...... n lupus membranous nephropathy
@en
P2093
Gabor G Illei
Howard A Austin
James E Balow
Michelle J Braun
P2860
P304
P356
10.1681/ASN.2008060665
P577
2009-03-18T00:00:00Z